Skip to Content

Generic Adasuve Availability

Adasuve is a brand name of loxapine, approved by the FDA in the following formulation(s):

ADASUVE (loxapine - powder;inhalation)

  • Manufacturer: ALEXZA PHARMS
    Approval date: December 21, 2012
    Strength(s): 10MG [RLD]

Has a generic version of Adasuve been approved?

No. There is currently no therapeutically equivalent version of Adasuve available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Adasuve. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Delivery of antipsychotics through an inhalation route
    Patent 6,716,416
    Issued: April 6, 2004
    Inventor(s): Joshua D.; Rabinowitz & Alejandro C.; Zaffaroni
    Assignee(s): Alexza Molecular Delivery Corporation
    The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antipsychotic. In a method aspect of the present invention, an antipsychotic is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an antipsychotic; and, b) a device that forms an antipsychotic containing aerosol from the composition, for inhalation by the mammal.
    Patent expiration dates:
    • May 20, 2022
      ✓ 
      Drug product
  • Delivery of antipsychotics through an inhalation route
    Patent 7,052,679
    Issued: May 30, 2006
    Inventor(s): Rabinowitz; Joshua D. & Zaffaroni; Alejandro C.
    Assignee(s): Alexza Pharmaceuticals, Inc.
    The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating a thin layer of an antipsychotic, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% antipsychotic drug degradation products. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route is provided which comprises: a) a thin film of an antipsychotic and b) a device for dispensing said thin film as a condensation aerosol.
    Patent expiration dates:
    • October 26, 2021
      ✓ 
      Drug product
  • Delivery of antipsychotics through an inhalation route
    Patent 7,078,020
    Issued: July 18, 2006
    Inventor(s): Rabinowitz; Joshua D. & Zaffaroni; Alejandro C.
    Assignee(s): Alexza Pharmaceuticals, Inc.
    The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% antipsychotic drug degradation products. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route is provided which comprises: a) a thin coating of an antipsychotic composition and b) a device for dispensing said thin coating as a condensation aerosol.
    Patent expiration dates:
    • October 26, 2021
      ✓ 
      Patent use: ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS
      ✓ 
      Drug product
  • Drug condensation aerosols and kits
    Patent 7,090,830
    Issued: August 15, 2006
    Inventor(s): Hale; Ron L. & Hodges; Craig C. & Lloyd; Peter M. & Lu; Amy T. & Myers; Daniel J. & Rabinowitz; Joshua D. & Wensley; Martin J.
    Assignee(s): Alexza Pharmaceuticals, Inc.
    The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1–3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 μm, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.
    Patent expiration dates:
    • October 26, 2021
      ✓ 
      Drug product
  • Method and apparatus for vaporizing a compound
    Patent 7,458,374
    Issued: December 2, 2008
    Inventor(s): Hale; Ron L. & Song; Soonho & Quintana; Reynaldo J. & Zaffaroni; Alejandro C. & Rabinowitz; Joshua D.
    Assignee(s): Alexza Pharmaceuticals, Inc.
    Disclosed is a method and device for rapid heating of a coated substance which preferably includes a drug to vaporized for inhalation therapy. A device in accordance with the present invention preferably includes a substrate which has an interior surface surrounding an interior region and an exterior surface upon which the coated substance is to be adhered. Though the substrate is preferably metallic, it does not need to be. A combustible element is placed in the interior region of the rigid substrate and an igniter is connected to the combustible element. The igniter is for initiating oxidation of the combustible element. Preferably, the coated substance is vaporized inside of a housing to allow the vaporized drug to aerosolize and be inhaled by a user.
    Patent expiration dates:
    • August 18, 2024
      ✓ 
      Drug product
  • Method of forming an aerosol for inhalation delivery
    Patent 7,537,009
    Issued: May 26, 2009
    Inventor(s): Hale; Ron L. & Hodges; Craig C. & Lloyd; Peter M. & Mufson; Daniel & Rogers; Daniel D. & Song; Soonho & Wensley; Martin J. & Myers; Daniel J. & McKinney; Jeffrey A. & Quintana; Reynaldo J. & Rabinowitz; Joshua D.
    Assignee(s): Alexza Pharmaceuticals, Inc.
    The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. In a method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug at a rate greater than 1000° C./s, thereby forming an vapor; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug to form a vapor, wherein the coated composition is in the form of a film less than 10 μ thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug to form a vapor in less than 100 milliseconds, wherein the vapor has a mass greater than 0.1 mg; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy.
    Patent expiration dates:
    • October 28, 2024
      ✓ 
      Drug product
  • Thin-film drug delivery article and method of use
    Patent 7,585,493
    Issued: September 8, 2009
    Inventor(s): Hale; Ron L. & Lu; Amy & Myers; Daniel J. & Rabinowitz; Joshua D. & Wensley; Martin J.
    Assignee(s): Alexza Pharmaceuticals, Inc.
    An article for use in an aerosol device, for producing an aerosol of a drug composition is disclosed. The article includes a heat-conductive substrate having a surface with a selected surface area, and a drug composition film on the substrate surface having a selected film thickness of between 0.05 and 20 μm. The film thickness is such that an aerosol formed by vaporizing the drug composition by heating the substrate and condensing the vaporized compound contains 10% or less drug-degradation product and at least 50% of the total amount of drug composition contained in the film. The selected substrate surface area is such as to yield an effective human therapeutic dose of the drug aerosol. Also disclosed are methods of making and using the article.
    Patent expiration dates:
    • October 26, 2021
      ✓ 
      Drug product
  • Delivery of antipsychotics through an inhalation route
    Patent 7,601,337
    Issued: October 13, 2009
    Inventor(s): Rabinowitz; Joshua D & Zaffaroni; Alejandro C
    Assignee(s): Alexza Pharmaceuticals, Inc.
    The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% antipsychotic drug degradation products. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route is provided which comprises: a) a thin coating of an antipsychotic composition and b) a device for dispensing said thin coating as a condensation aerosol.
    Patent expiration dates:
    • October 26, 2021
      ✓ 
      Drug product
  • Method of forming an aerosol for inhalation delivery
    Patent 8,074,644
    Issued: December 13, 2011
    Inventor(s): Hale; Ron L. & Hodges; Craig C. & Lloyd; Peter M. & Mufson; Daniel & Rogers; Daniel D. & Song; Soonho & Wensley; Martin J. & Myers; Daniel J. & McKinney; Jeffrey A. & Quintana; Reynaldo J. & Rabinowitz; Joshua D.
    Assignee(s): Alexza Pharmaceuticals, Inc.
    The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. In a method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug at a rate greater than 1000° C./s, thereby forming an vapor; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug to form a vapor, wherein the coated composition is in the form of a film less than 10μ thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug to form a vapor in less than 100 milliseconds, wherein the vapor has a mass greater than 0.1 mg; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy.
    Patent expiration dates:
    • July 25, 2022
      ✓ 
      Drug product
  • Delivery of antipsychotics through an inhalation route
    Patent 8,173,107
    Issued: May 8, 2012
    Inventor(s): Rabinowitz; Joshua D. & Zaffaroni; Alejandro C.
    Assignee(s): Alexza Pharmaceuticals, Inc.
    The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% antipsychotic drug degradation products. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route is provided which comprises: a) a thin coating of an antipsychotic composition and b) a device for dispensing said thin coating as a condensation aerosol.
    Patent expiration dates:
    • October 26, 2021
      ✓ 
      Drug product
  • Drug condensation aerosols and kits
    Patent 8,235,037
    Issued: August 7, 2012
    Inventor(s): Hale; Ron L. & Hodges; Craig C. & Lloyd; Peter M. & Lu; Amy T. & Myers; Daniel J. & Rabinowitz; Joshua D. & Wensley; Martin J. & McKinney; Jeffrey A. & Zaffaroni; Alejandro C.
    Assignee(s): Alexza Pharmaceuticals, Inc.
    The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 μm, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.
    Patent expiration dates:
    • October 26, 2021
      ✓ 
      Drug product
  • Self-contained heating unit and drug-supply unit employing same
    Patent 8,387,612
    Issued: March 5, 2013
    Assignee(s): Alexza Pharmaceuticals, Inc.
    Heating units, drug supply units and drug delivery articles capable of rapid heating are disclosed. Heating units comprising a substrate and a solid fuel capable of undergoing an exothermic metal oxidation reaction disposed within the substrate are disclosed. These heating units can be actuated by electrical resistance, by optical ignition or by percussion. Drug supply units and drug delivery articles wherein a solid fuel is configured to heat a substrate to a temperature sufficient to rapidly thermally vaporize a drug disposed thereon are also disclosed.
    Patent expiration dates:
    • October 23, 2026
      ✓ 
      Drug product
  • Method of forming an aerosol for inhalation delivery
    Patent 8,955,512
    Issued: February 17, 2015
    Assignee(s): Alexza Pharmaceuticals, Inc.
    The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. The method involves: (a) heating a substrate coated with a composition comprising a drug to form a vapor, wherein the coated composition is in the form of a film less than 10μ thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another aspect, a method of forming an aerosol for use in inhalation therapy is provided, wherein the method comprises: (a) heating a substrate coated with a composition comprising a drug to form a vapor in less than 100 milliseconds, wherein the vapor has a mass greater than 0.1 mg; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy.
    Patent expiration dates:
    • October 26, 2021
      ✓ 
      Drug product
  • Self-contained heating unit and drug-supply unit employing same
    Patent 8,991,387
    Issued: March 31, 2015
    Assignee(s): Alexza Pharmaceuticals, Inc.
    Heating units, drug supply units and drug delivery articles capable of rapid heating are disclosed. Heating units comprising a substrate and a solid fuel capable of undergoing an exothermic metal oxidation reaction disposed within the substrate are disclosed. These heating units can be actuated by electrical resistance, by optical ignition or by percussion. Drug supply units and drug delivery articles wherein a solid fuel is configured to heat a substrate to a temperature sufficient to rapidly thermally vaporize a drug disposed thereon are also disclosed.
    Patent expiration dates:
    • May 21, 2024
      ✓ 
      Drug product
  • Self-contained heating unit and drug-supply unit employing same
    Patent 9,370,629
    Issued: June 21, 2016
    Assignee(s): ALEXZA PHARMACEUTICALS, INC.
    Heating units, drug supply units and drug delivery articles capable of rapid heating are disclosed. Heating units comprising a substrate and a solid fuel capable of undergoing an exothermic metal oxidation reaction disposed within the substrate are disclosed. These heating units can be actuated by electrical resistance, by optical ignition or by percussion. Drug supply units and drug delivery articles wherein a solid fuel is configured to heat a substrate to a temperature sufficient to rapidly thermally vaporize a drug disposed thereon are also disclosed.
    Patent expiration dates:
    • May 20, 2024
      ✓ 
      Drug product
  • Method of forming an aerosol for inhalation delivery
    Patent 9,439,907
    Issued: September 13, 2016
    Assignee(s): ALEXZA PHARMACEUTICAL, INC.
    The present application relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. The method involves: (a) heating a substrate coated with a composition of a drug to form a vapor, wherein the coated composition is in the form of a film less than 10μ thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another aspect, a method of forming an aerosol for use in inhalation therapy is provided, wherein the method involves: (a) heating a substrate coated with a composition of a drug to form a vapor in less than 100 milliseconds, wherein the vapor has a mass greater than 0.1 mg; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy.
    Patent expiration dates:
    • October 26, 2021
      ✓ 
      Drug product
  • Drug condensation aerosols and kits
    Patent 9,440,034
    Issued: September 13, 2016
    Assignee(s): ALEXZA PHARMACEUTICALS, INC.
    The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 μm, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.
    Patent expiration dates:
    • October 26, 2021
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 21, 2015 - NEW DOSAGE FORM

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide